CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
January 2019—The FDA approved Truxima (rituximab-abbs, Celltrion) as the first biosimilar to Rituxan (rituximab, Genentech) for patients with CD20-positive, B-cell non-Hodgkin lymphoma to be used as a single agent or in combination with chemotherapy.
Truxima is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent; previously untreated follicular, CD20-positive B-cell NHL in combination with first-line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as a single-agent maintenance therapy; and non-progressing (including stable disease), low-grade, CD20-positive B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone chemotherapy.